Clinical Trials on Flavopiridol

Search results for Flavopiridol [ALL-FIELDS] are shown below.
Include trials that are no longer recruiting patients.
http://clinicaltrials.gov/ct/action/GetStudy
52 studies were found. Here are studies 1 to 50.
1. Recruiting Flavopiridol in Treating Patients With Relapsed or
Refractory Lymphoma or Multiple Myeloma
Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
2. Recruiting Vorinostat and Flavopiridol in Treating Patients With
Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
3. Recruiting Bortezomib and Flavopiridol in Treating Patients With
Recurrent or Refractory Indolent B-Cell Neoplasms
Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
4. Recruiting Flavopiridol, Oxaliplatin, Fluorouracil, and Leucovorin in
Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
5. Recruiting Flavopiridol in Treating Patients With Chronic Lymphocytic
Leukemia or Prolymphocytic Leukemia
Condition: Leukemia
6. Recruiting Flavopiridol in Treating Patients With Metastatic or
Unresectable Refractory Solid Tumors or Hematologic Malignancies
Conditions: Breast Cancer; Head and Neck Cancer; Intraocular Melanoma;
Kidney Cancer; Leukemia; Lung Cancer; Lymphoma; Malignant Mesothelioma;
Melanoma (Skin); ...
7. Recruiting Flavopiridol Plus Radiation Therapy Followed By Gemcitabine
in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Condition: Pancreatic Cancer
8. Active, not recruiting Flavopiridol in Treating Patients With
Metastatic Malignant Melanoma
Condition: Melanoma (Skin)
9. Active, not recruiting Flavopiridol in Treating Patients With
Previously Untreated or Relapsed Mantle Cell Lymphoma
Condition: Lymphoma
10. Active, not recruiting Flavopiridol in Treating Patients With
Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Condition: Sarcoma
11. Suspended Flavopiridol in Treating Patients With Locally Advanced or
Metastatic Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
12. Completed Flavopiridol and Imatinib Mesylate in Treating Patients
With Hematologic Cancer
Condition: Leukemia
13. Recruiting Docetaxel and Flavopiridol in Treating Patients With
Refractory Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
14. Recruiting FR901228 and Flavopiridol in Treating Patients With
Advanced Lung, Esophageal, or Pleural Cancer
Conditions: Esophageal Cancer; Lung Cancer; Malignant Mesothelioma;
Metastatic Cancer
15. Recruiting Flavopiridol and Vorinostat in Treating Patients With
Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or
Refractory Anemia
Conditions: Leukemia; Myelodysplastic Syndromes
16. Recruiting Doxorubicin and Flavopiridol in Treating Patients With
Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
Conditions: Gastrointestinal Stromal Tumor; Sarcoma
17. Active, not recruiting Flavopiridol, Gemcitabine, and Irinotecan in
Treating Patients With Unresectable or Metastatic Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
18. Recruiting Gemcitabine and Flavopiridol in Treating Patients With
Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
19. Completed Trastuzumab and Flavopiridol in Treating Patients With
Metastatic Breast Cancer
Condition: Breast Cancer
20. Active, not recruiting Flavopiridol, Fludarabine, and Rituximab in
Treating Patients With Lymphoproliferative Disorders or Mantle Cell
Lymphoma
Conditions: Leukemia; Lymphoma
21. Completed Irinotecan and Flavopiridol in Treating Patients With
Advanced Liver Cancer
Condition: Liver Cancer
22. Recruiting Cisplatin and Flavopiridol in Treating Patients With
Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer; Peritoneal Cavity Cancer
23. Recruiting Flavopiridol in Treating Patients With Refractory or
Recurrent Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
24. Active, not recruiting Flavopiridol in Treating Patients With
Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Conditions: Leukemia; Lymphoma
25. Recruiting Flavopiridol in Treating Patients With Relapsed or
Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or
Chronic Myelogenous Leukemia
Condition: Leukemia
26. Recruiting Flavopiridol in Treating Patients With B-Cell Chronic
Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Leukemia; Lymphoma
27. Recruiting Flavopiridol, Cytarabine, and Mitoxantrone in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Leukemia
28. Recruiting Flavopiridol, Cytarabine, and Mitoxantrone in Treating
Patients With Relapsed or Refractory Acute Leukemia
Condition: Leukemia
29. Completed Flavopiridol in Treating Patients With Recurrent Prostate
Cancer
Condition: Prostate Cancer
30. Completed Flavopiridol in Treating Patients With Refractory Cancer
Conditions: Lymphoma; Prostate Cancer; Small Intestine Cancer; Unspecified
Adult Solid Tumor, Protocol Specific
31. Active, not recruiting Flavopiridol in Treating Patients With
Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
32. Completed Flavopiridol and Docetaxel in Treating Patients With
Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
33. Active, not recruiting Flavopiridol Plus Cisplatin or Carboplatin in
Treating Patients With Advanced Solid Tumors
Conditions: Breast Cancer; Melanoma (Skin); Prostate Cancer; Unspecified
Adult Solid Tumor, Protocol Specific
34. Completed Flavopiridol in Treating Patients With Chronic Lymphocytic
Leukemia
Condition: Leukemia
35. Completed Flavopiridol in Treating Patients With Recurrent or
Persistent Endometrial Cancer
Condition: Endometrial Cancer
36. Completed Flavopiridol in Treating Patients With Unresectable or
Metastatic Kidney Cancer
Condition: Kidney Cancer
37. Active, not recruiting Flavopiridol in Treating Children With
Relapsed or Refractory Solid Tumors or Lymphomas
Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell
Tumor; Kidney Cancer; Liver Cancer; Lymphoma; Retinoblastoma; Sarcoma; ...

38. Active, not recruiting Flavopiridol and Irinotecan in Treating
Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
39. Completed Flavopiridol in Treating Patients With Recurrent or
Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer; Thromboembolism
40. Active, not recruiting Gemcitabine Plus Flavopiridol in Treating
Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
41. Completed Flavopiridol and Paclitaxel in Treating Patients With
Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to
Previous Paclitaxel
Condition: Esophageal Cancer
42. Completed Flavopiridol, Cytarabine, and Mitoxantrone in Treating
Patients With Acute Leukemia
Condition: Leukemia
43. Completed Flavopiridol in Treating Patients With Recurrent
Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell
Lymphoma
Condition: Lymphoma
44. Recruiting Alvocidib in Patients With Previously Treated Chronic
Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From CLL
Condition: Leukemia, Lymphocytic, Chronic
45. Completed Genetic Study of Patients Previously Treated With
Flavopiridol on Clinical Trial NCI-97-C-0171C
Condition: Unspecified Adult Solid Tumor, Protocol Specific
46. Recruiting Combination Chemotherapy in Treating Patients With
Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
47. Completed Docetaxel and Flavopiridol in Treating Patients With
Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
48. Active, not recruiting Combination Chemotherapy in Treating Patients
With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
49. Active, not recruiting Combination Chemotherapy in Treating Patients
With Advanced Cancer
Condition: Unspecified Adult Solid Tumor, Protocol Specific
50. Active, not recruiting Combination Chemotherapy in Treating Patients
With Refractory or Recurrent Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
52 studies were found. Here are studies 51 to 52.
51. Recruiting Combination Chemotherapy in Treating Patients With Locally
Advanced or Metastatic Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
52. Completed Chemical and Genetic Effects of the Experimental
Anti-Cancer Drugs in Cheek Cells in Cancer Patients
Condition: Cancer

.